Ilenia Panasiti

Ilenia Panasiti

Auto-generated profile, based on publicly available information

Ilenia Panasiti

Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Allergy Unit, University of Messina, Messina, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2018 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
Stefano PassanisiStefano Passanisi
Stefano Passanisi
FLFortunato Lombardo
Fortunato Lombardo
ABAndrea Barbalace
Andrea Barbalace
LCLucia Caminiti
Lucia Caminiti
IPIlenia Panasiti
Ilenia Panasiti
GPGiovanni B. Pajno
Giovanni B. Pajno

1 April 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
FLFortunato Lombardo
Fortunato Lombardo
GSGiuseppina Salzano
Giuseppina Salzano
GCGiuseppe Crisafulli
Giuseppe Crisafulli
IPIlenia Panasiti
Ilenia Panasiti
AAAngela Alibrandi
Angela Alibrandi
Stefano PassanisiStefano Passanisi
Stefano Passanisi

1 November 2017 in Cytokine
Verified
Journal Article
Closed access
Sara MantiSara Manti
Sara Manti
SLS. Leonardi
S. Leonardi
IPI. Panasiti
I. Panasiti
TAT. Arrigo
T. Arrigo
CSC. Salpietro
C. Salpietro
CCC. Cuppari
C. Cuppari

13 December 2019 in Allergy
Verified
Journal Article
Open access
PDF file
THTara Maria Hoffmann
Tara Maria Hoffmann
AŞAydan Acar Şahin
Aydan Acar Şahin
XAXenophon Aggelidis
Xenophon Aggelidis
SAStefania Arasi
Stefania Arasi
ABAndrea Barbalace
Andrea Barbalace
NPNm Pinar
Nm Pinar
Background: The adequate definition of pollen seasons is essential to facilitate a correct diagnosis, treatment choice, and outcome assessment in patients with seasonal allergic rhinitis. A position paper by the European Academy of Allergy and Clinical Immunology (EAACI) proposed season definitions for Northern and Middle Europe.Objective: To test the pollen season definitions proposed by EAACI in six Mediterranean cities for seven pollen taxa.Methods: As part of the @IT.2020 multi‐center study, pollen counts for Poaceae, Oleaceae, Fagales, Cupressaceae, Urticaceae (Parietaria spp.), and Compositae (Ambrosia spp., Artemisia spp.) were collected from January 1 to December 31, 2018. Based on these data, pollen seasons were identified according to EAACI criteria. A unified monitoring period for patients in AIT trials was created and assessed for feasibility.Results: The analysis revealed a great heterogeneity between the different locations in terms of pattern and length of the examined pollen seasons. Further, we found a fragmentation of pollen seasons in several segments (max. 8) separated by periods of low pollen counts (intercurrent periods). Potential monitoring periods included often many recording days with low pollen exposure (max. 341 days).Conclusion: The Mediterranean climate leads to challenging pollen exposure times. Monitoring periods for AIT trials based on existing definitions may include many intermittent days with low pollen concentrations. Therefore, it is necessary to find an adapted pollen season definition as individual solution for each pollen and geographical area.

14 January 2019 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
GCGiuseppe Crisafulli
Giuseppe Crisafulli
LCLucia Caminiti
Lucia Caminiti
FCFernanda Chiera
Fernanda Chiera
SAStefania Arasi
Stefania Arasi
GSGiuseppina SALZANO
Giuseppina SALZANO
GPGiovanni Battista Pajno
Giovanni Battista Pajno
Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy. Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol. Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies. Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.

1 January 2019 in World Allergy Organization Journal
Verified
Journal Article
Open access
SAStefania Arasi
Stefania Arasi
LCLucia Caminiti
Lucia Caminiti
GCGiuseppe Crisafulli
Giuseppe Crisafulli
IPIlenia Panasiti
Ilenia Panasiti
ABAndrea Barbalace
Andrea Barbalace
GPGiovanni Battista Pajno
Giovanni Battista Pajno